Translating computational predictions into experimentally validated biological knowledge remains one of the central challenges in modern bioinformatics. This review critically examines how in silico findings can be prioritized, tested, and interpreted through experimental validation. We organize the validation process around three recurring challenges: the specificity gap between genome-wide computational predictions and single-target experimental assays; the reproducibility-translatability tension, in which results validated in one model system may not generalize to another; and the scale-depth trade-off between high-throughput candidate discovery and the low-throughput nature of mechanistic validation. Rather than presenting an encyclopedic catalogue of techniques, we compare the strengths, limitations, and common failure modes of major validation approaches, including qPCR, RNA-seq, Western blotting, co-immunoprecipitation, luciferase reporter assays, CRISPR perturbation, and functional phenotypic assays. We also provide structured comparison tables for gene expression, protein-protein interaction, non-coding RNA, regulatory element, and pathway validation, together with decision-making frameworks to guide method selection according to prediction type, biological context, evidence stringency, throughput, and resource constraints. Case studies from cancer genomics, drug target discovery, miRNA regulation, and neurological disease illustrate how multi-step validation workflows can strengthen causal inference and reduce false-positive interpretation. Finally, we discuss how emerging technologies, including CRISPR screens, single-cell and spatial multi-omics, and AI-assisted experimental design, may reshape validation practice by improving scalability, context specificity, and reproducibility.

翻译：暂无翻译